{
    "id": 967,
    "fullName": "BCL2L1 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type BCL2L1 indicates no mutation has been detected in the BCL2L1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 598,
        "geneSymbol": "BCL2L1",
        "terms": [
            "BCL2L1",
            "Bcl-X",
            "BCL-XL/S",
            "BCL2L",
            "BCLX",
            "PPP1R52"
        ]
    },
    "variant": "wild-type",
    "createDate": "07/11/2014",
    "updateDate": "06/12/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1155463 induced apoptosis in a BCL2L1 (BCL-XL)-dependent small cell lung cancer cell line in culture (PMID: 25787766).",
            "molecularProfile": {
                "id": 1027,
                "profileName": "BCL2L1 wild-type"
            },
            "therapy": {
                "id": 2576,
                "therapyName": "A-1155463",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2473,
                    "pubMedId": 25787766,
                    "title": "Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25787766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17281,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Navitoclax (ABT-263) and YM-155 did not inhibit growth of colorectal cancer patient-derived xenografts with BCL2L1 wild-type and and KRAS wild-type (PMID: 28611106).",
            "molecularProfile": {
                "id": 32468,
                "profileName": "BCL2L1 wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 8445,
                "therapyName": "Navitoclax + YM155",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15327,
                    "pubMedId": 28611106,
                    "title": "A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611106"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1027,
            "profileName": "BCL2L1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32468,
            "profileName": "BCL2L1 wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}